Aminopeptidase inhibitors - Pipeline Insight, 2024

Aminopeptidase inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Aminopeptidase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Aminopeptidase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Aminopeptidase inhibitors Understanding

Aminopeptidase inhibitors: Overview

Aminopeptidases, which are widely distributed in nature, are one of the two major subclasses of the exopeptidases, proteolytic enzymes that remove amino acids from the termini of peptides and proteins (the other being the carboxypeptidases). As the name indicates, the aminopeptidases attack their substrates exclusively from the amino terminal end. Aminopeptidase A (APA), also known as a glutamyl aminopeptidase and CD249, cleaves the N-terminal residue of AngII to form Ang-(2-8), also known as angiotensin-III (AngIII). Methionine aminopeptidase (MetAP) catalyzes the hydrolytic cleavage of the N-terminal methionine from newly synthesized polypeptides.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Aminopeptidase inhibitors R&D. The therapies under development are focused on novel approaches for Aminopeptidase inhibitors.

Aminopeptidase inhibitors Emerging Drugs Chapters

This segment of the Aminopeptidase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aminopeptidase inhibitors Emerging Drugs

• Firibastat: Quantum Genomics

The firibastat (originally named QGC001) product is the first BAPAI candidate-drug selected by Quantum Genomics. The firibastat product is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiontensin III in the brain. Due to its unique action mechanism, firibastat represents an alternative therapeutic approach which can interfere with the mechanisms involved in the genesis and control of blood pressure in hypertensive patients, especially those with a particular hormonal profile, characterized by a low renin concentration and a high vasopressin concentration (Low Renin High Vasopressin (LRHV) profile). Firibastat and its therapeutic use are strongly protected by several families of patents ensuring an industrial protection until 2033 without taking into consideration the potential additional protection certificates.

• APL-1202: Asieris Pharmaceuticals

APL-1202 is an innovative oncology drug developed by Asieris Pharmaceuticals over the past decade after in-licensing the patented technology from Johns Hopkins University in the United States. As the first-in-class oral and reversible methionine aminopeptidase 2 (MetAP2) inhibitor to enter a pivotal/phase III clinical trial, APL-1202 is the world’s first oral targeted therapy for non-muscle invasive bladder cancer (NMIBC) under a pivotal/phase III clinical trial. At the same time, APL-1202 is also being developed for preoperative neoadjuvant treatment of muscle invasive bladder cancer (MIBC).

Further product details are provided in the report……..

Aminopeptidase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Aminopeptidase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Aminopeptidase inhibitors

There are approx. 5+ key companies which are developing the Aminopeptidase inhibitors. The companies which have their Aminopeptidase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Quantum Genomics.

• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Aminopeptidase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aminopeptidase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aminopeptidase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aminopeptidase inhibitors drugs.

Aminopeptidase inhibitors Report Insights

• Aminopeptidase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Aminopeptidase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Aminopeptidase inhibitors drugs?
• How many Aminopeptidase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aminopeptidase inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aminopeptidase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aminopeptidase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Quantum Genomics
• Asieris Pharmaceuticals
• Pharmaleads
• EMD Serono
• SynDevRx, Inc
• Larimar Therapeutics

Key Products

• Firibastat
• APL-1202
• APL 1501
• PL 37
• PL 265
• M 8891
• SDX 7195
• SDX 7320
• Aclimostat
• QGC-006